These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27910101)

  • 1. Early safety and efficacy of fingolimod treatment in Denmark.
    Voldsgaard A; Koch-Henriksen N; Magyari M; Sellebjerg F; Sørensen PS; Oturai AB
    Acta Neurol Scand; 2017 Jan; 135(1):129-133. PubMed ID: 27910101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
    Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.
    DiMarco JP; O'Connor P; Cohen JA; Reder AT; Zhang-Auberson L; Tang D; Collins W; Kappos L
    Mult Scler Relat Disord; 2014 Sep; 3(5):629-38. PubMed ID: 26265275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
    Limmroth V; Ziemssen T; Lang M; Richter S; Wagner B; Haas J; Schmidt S; Gerbershagen K; Lassek C; Klotz L; Hoffmann O; Albert C; Schuh K; Baier-Ebert M; Wendt G; Schieb H; Hoyer S; Dechend R; Haverkamp W
    BMC Neurol; 2017 Jan; 17(1):11. PubMed ID: 28100182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
    Brown B; Weiss JL; Kolodny S; Meng X; Williams IM; Osborne JA
    BMC Neurol; 2019 Nov; 19(1):287. PubMed ID: 31729968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
    Akbulak RÖ; Rosenkranz SC; Schaeffer BN; Pinnschmidt HO; Willems S; Heesen C; Hoffmann BA
    Mult Scler Relat Disord; 2018 Jan; 19():44-49. PubMed ID: 29127856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
    Tichá V; Kodým R; Počíková Z; Kadlecová P
    Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A longitudinal real-life comparison study of natalizumab and fingolimod.
    Lanzillo R; Carotenuto A; Moccia M; Saccà F; Russo CV; Massarelli M; De Rosa A; Brescia Morra V
    Acta Neurol Scand; 2017 Sep; 136(3):217-222. PubMed ID: 27976804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of fingolimod in a Portuguese real-world population.
    Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
    Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
    Gold R; Comi G; Palace J; Siever A; Gottschalk R; Bijarnia M; von Rosenstiel P; Tomic D; Kappos L;
    J Neurol; 2014 Feb; 261(2):267-76. PubMed ID: 24221641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
    Puz P; Lasek-Bal A
    Med Sci Monit; 2016 Nov; 22():4277-4282. PubMed ID: 27829656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
    Bianco A; Patanella AK; Nociti V; Marti A; Frisullo G; Plantone D; De Fino C; Fetta A; Batocchi AP; Rossini PM; Mirabella M
    Eur Neurol; 2015; 73(1-2):57-65. PubMed ID: 25402749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
    Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
    Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod effects on left ventricular function in multiple sclerosis.
    Racca V; Di Rienzo M; Cavarretta R; Toccafondi A; Vaini E; Ferratini M; Rovaris M
    Mult Scler; 2016 Feb; 22(2):201-11. PubMed ID: 26041795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
    Datt J; Baldock L; Pull E; Webber B
    Mult Scler Relat Disord; 2016 Jan; 5():40-6. PubMed ID: 26856942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
    Mult Scler Relat Disord; 2016 Nov; 10():86-89. PubMed ID: 27919506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran.
    Ouspid E; Razazian N; Moghadasi AN; Moradian N; Afshari D; Bostani A; Sariaslani P; Ansarian A
    Neurosciences (Riyadh); 2018 Apr; 23(2):129-134. PubMed ID: 29664454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.